Clinical Trial

Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
In this study, a single dose of VIR-2218 up to 200 mg SC or VIR-3434 at 300 mg SC monotherapy or a combination of VIR-2218 and VIR-3434 will be administered to assess the pharmacokinetic (PK) exposure, safety, and tolerability of VIR-2218 and VIR-3434 in participants with cirrhosis and Hepatic Impairment, defined using the Child-Pugh-Turcotte (CPT) categorization.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-07-29; most recent amendment 2025-06-10.
Status change: Not Yet Recruiting → Recruiting 2022-08-30
Trial Details
NCT Number NCT05484206
Lead Sponsor Vir Biotechnology, Inc.
Conditions Hepatic Impairment, Cirrhosis
Enrollment 144 participants
Start Date 2022-09-21
Primary Completion 2026-09-25 (estimated)
Study Completion 2027-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-13